Agrawal Ritesh
Department of Chemistry, Shrimant Madhavrao Scindia, Government Model Science College, Jhansi Road, Gwalior, Madhya Pradesh, PIN No. 474001, India.
Curr Drug Targets. 2014 Feb;15(2):151-5. doi: 10.2174/13894501113149990199.
The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in June 2013. Lipaglyn is indicated for the patients suffering from diabetes dyslipidemia. It also provides the option of a once-daily oral therapy. Saroglitazar regulates the lipid parameters as well as glycemic control. The present article describes Saroglitazar with its chemical synthesis and patent status with its summary of clinical studies.
这种新化学实体（NCE）已被视为新型抗糖尿病药物，例如沙罗格列扎。沙罗格列扎是一种用于治疗II型糖尿病的药物。沙罗格列扎以商品名Lipaglyn销售，由Zydus Cadila公司研发。Lipaglyn是印度任何一家制药公司有史以来首个本土研发的NCE。Lipaglyn于2013年6月获得印度药品总监批准用于治疗II型糖尿病。Lipaglyn适用于患有糖尿病血脂异常的患者。它还提供了每日一次口服治疗的选择。沙罗格列扎可调节血脂参数以及控制血糖。本文介绍了沙罗格列扎及其化学合成、专利状态以及临床研究总结。
